The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2016:
32 negotiations are currently underway with 2 files added since the last update of June 30, 2016:
Avastin (bevacizumab): used to treat genitourinary platinum-resistant ovarian cancer
Opdivo (nivolumab): used to ... Read More
17
Aug2016
12
Aug2016
*Tuesday, August 17th Webinar CANCELLED*
We regret to inform you that the webinar session on Wednesday, August 17th, 2016 from 10:00 a.m. to 12:00 p.m. (noon) is cancelled due to unforeseen technical issues. We wanted to give as much notice as possible so individuals can register for the alternate date (Tuesday, ... Read More
10
Aug2016
On June 24, 2016, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. Are you interested in learning more about the potential repercussions of these changes on Canadian drug prices and implications for pharmaceutical companies?
PDCI Market Access Inc., Canada’s leading pricing and reimbursement ... Read More
05
Aug2016
Results of the Notice and Comment Period on Incremental Reforms to the Compendium of Policies, Guidelines and Procedures
On December 4, 2015, the PMPRB announced the start of a Notice and Comment initiative to seek stakeholder feedback on two proposed amendments to the Compendium of Policies, Guidelines and Procedures: the “Reasonable ... Read More
29
Jul2016
PDCI’s PMPRB Guidelines Modernization Webinar Session
On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range ... Read More
21
Jul2016
Correction to the below TargetPharma (“PMPRB 2015 Annual Report”) sent out on July 21, 2016.
The PMPRB report tabled in Parliament was their report with respect to the Access to Information Act and to the Privacy Act and not the anticipated “2015 PMPRB Annual Report” which was not tabled and now ... Read More
12
Jul2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2016:
33 negotiations are currently underway with 8 files (including 2 biosimilars) added since the last update of May 31, 2016:
Abilify (aripiprazole): used for the treatment of schizophrenia and related ... Read More
04
Jul2016
On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range of issues that will inform ... Read More
27
Jun2016
Discussion Paper. On Friday June 24, the PMPRB released a long delayed discussion paper covering a wide range of issues that go to the core of the PMPRB’s price regulation mandate. The PMPRB will be seeking input from stakeholders over the Summer/Fall of 2016 and will hold public policy hearings ... Read More
20
Jun2016
In February 2015, PDCI Market Access (PDCI) released a report entitled pCPA Negotiation Guidelines. That report, which was a collaboration between the pan-Canadian Pharmaceutical Alliance (pCPA) and PDCI, was meant to provide guidance to manufacturers on pCPA’s expectations surrounding negotiations.
Although the pCPA Negotiation Guidelines report outlined how manufacturers should ... Read More